CME Internet Symposium

CROI21_Web_Banner_v1.jpg

 

CROI21_Launch_Button

 

   

About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 28th Conference on Retroviruses and Opportunistic Infections (CROI 2021). This program consists of two components: (1) From Conference to Clinic: Reviewing and Applying Data from CROI 2021: a case-based webcast featuring expert faculty reviewing key presentations with a focus on clinical management and treatment; (2) CROI 2021 e-Newsletter: a brief on-line summary of the most essential data presented at the conference.

The CME Internet Symposium: From Conference to Clinic: Reviewing and Applying Data from CROI 2021 will feature a panel of HIV experts reviewing key presentations on antiretroviral therapy presented at CROI 2021. The review will include several clinical cases focusing on HIV therapeutic options and developments, including: current treatment and management strategies; algorithms and recommendations; therapies in development; epidemiology, diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All on-line components of the program can be accessed at www.viraled.com.

This program is jointly provided by the Postgraduate Institute for Medicine and ViralEd. It is not a session created by or presented at CROI 2021 and it is not sanctioned by the organizers of CROI 2021.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use optimal ARV therapy to all people with HIV infection
  • Describe the impact of ARV adverse events on treatment success and be able to adjust ARV regimens to maximize tolerability
  • Identify ARV adverse effects, especially neuropsychiatric effects and weight gain, and adjust ARV regimens to minimize these effects
  • Recognize mental health issues, such as stress, anxiety, depression, and substance use, in patients being treated for HIV infection, and employ approaches for addressing these mental health issues

Release Date: March 19, 2021

Expiration Date: March 19, 2022

Estimated time to complete each Module: 30-45 minutes 

Media: Web

Back to Top

 

Faculty

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom 

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany

Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois 

Back to Top

Joint Accreditation Statement and Credit Designation

Jointly-Accredited-Provider-TM_1000x636 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Module 1 (COVID-19 and COIVID-19/HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2 (Hepatitis and PrEP):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3 (HIV Treatment Experienced Patients): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 4 (Comorbidities and Adverse Events):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:

Jose Arribas, MD

  • Consulting Fees: Janssen, MSD, ViiV, Alexa, Teva, Gilead, Serono
  • Contracted Research: ViiV, Gilead

Graeme Moyle, MD

  • Consulting Fees: Theratechnologies, Gilead, ViiV, Merck/MSD
  • Other (Patient Advice): Novartis

Jürgen Rockstroh, MD

  • Consulting Fees: Abivax, Gilead, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Merck, Janssen, ViiV

Paul Sax, MD

  • Consulting Fees: Gilead, GSK/ViiV, Janssen, Merck
  • Contracted Research: Gilead, GSK/ViiV, Merck
  • Other (Editorial Boards): Medscape, UpToDate, NEJM Journal Watch, Open Forum ID

Renslow Sherer, MD

  • Contracted Research: Gilead
The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose

 

Back to Top

Method of Participation and Request for Credit

1) Go to http://www.cmeuniversity.com/

2) Login or Create a New Account (will take less than 1 minute)
   a) If you receive a message when creating a new account that "the email you entered is already in use", please click the Forgot my Username or Password link to have your Username and Password sent to you via email
   b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 15990 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) (If applicable) Complete the Post-test with a passing score of 75% or better
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

 

 

    PIM_small            VE logo 300px

 

 

This activity is supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products LP.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

*Greenwich Mean Time

 

Back to Top

 

     

Prepare to print

Share this page:

Get link code to this page     


Back to Top